Gainers at Biotech: Alcobra (NASDAQ:ADHD), Aratana Therapeutics (NASDAQ:PETX), Northwest Biotherapeutics (NASDAQ:NWBO), Agenus Inc (NASDAQ:AGEN), AEterna Zentaris (NASDAQ:AEZS)

Research analysts at WBB Securities initiated coverage on shares of Alcobra Ltd (NASDAQ:ADHD) in a report released on Thursday, 26 June 2014. The firm set a “hold” rating and a $18.00 price target on the stock. WBB Securities’ target price points to a potential upside of 5.76% from the company’s current price. Alcobra Ltd (NASDAQ:ADHD) stock performance was 5.85% in last session and finished the … Continue reading Gainers at Biotech: Alcobra (NASDAQ:ADHD), Aratana Therapeutics (NASDAQ:PETX), Northwest Biotherapeutics (NASDAQ:NWBO), Agenus Inc (NASDAQ:AGEN), AEterna Zentaris (NASDAQ:AEZS)

Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, … Continue reading Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Healthcare Stocks In News: Ultragenyx (NASDAQ:RARE), Flexion (NASDAQ:FLXN), Receptos Inc (NASDAQ:RCPT), Acorda Therapeutics (NASDAQ:ACOR), Aratana Therapeutics (NASDAQ:PETX)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is up over 16% today on news of the company’s initiation of phase-II trials for its lead drug candidate KRN23, which is a monoclonal antibody for X-linked Hypophosphatemia (XLH). Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock performance was 14.30% in last session and finished the day at $48.67. Traded volume was 435,645.00million shares in the last session and the average volume of the … Continue reading Healthcare Stocks In News: Ultragenyx (NASDAQ:RARE), Flexion (NASDAQ:FLXN), Receptos Inc (NASDAQ:RCPT), Acorda Therapeutics (NASDAQ:ACOR), Aratana Therapeutics (NASDAQ:PETX)